These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 18353498)

  • 41. Cold comfort.
    Gallagher R
    Nurs Times; 1999 Jan 13-19; 95(2):55-6. PubMed ID: 10067603
    [No Abstract]   [Full Text] [Related]  

  • 42. Stenotrophomonas maltophilia keratitis after penetrating keratoplasty.
    Fernandes M; Gangopadhyay N; Sharma S
    Eye (Lond); 2005 Aug; 19(8):921-3. PubMed ID: 15761487
    [No Abstract]   [Full Text] [Related]  

  • 43. Rates of Stenotrophomonas maltophilia colonization and infection in relation to antibiotic cycling protocols.
    Pakyz AL; Farr BM
    Epidemiol Infect; 2009 Dec; 137(12):1679-83. PubMed ID: 19874637
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ralstonia associated with Vapotherm oxygen delivery device--United States, 2005.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2005 Oct; 54(41):1052-3. PubMed ID: 16237377
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Improved isolation of Stenotrophomonas maltophilia from the sputa of patients with cystic fibrosis using a selective medium.
    Denton M; Hall MJ; Todd NJ; Kerr KG; Littlewood JM
    Clin Microbiol Infect; 2000 Jul; 6(7):397-8. PubMed ID: 11168159
    [No Abstract]   [Full Text] [Related]  

  • 46. [Stenotrophomonas maltophilia and cancer].
    Cuervo M SI; Martínez LM; Arroyo A CP
    Rev Chilena Infectol; 2008 Oct; 25(5):400. PubMed ID: 18949155
    [No Abstract]   [Full Text] [Related]  

  • 47. Medical devices for cystic fibrosis care may be portable reservoirs of potential pathogens.
    Linnane B; Collins L; Bussmann N; O'Connell NH; Dunne CP
    J Hosp Infect; 2017 Aug; 96(4):397-398. PubMed ID: 28535966
    [No Abstract]   [Full Text] [Related]  

  • 48. Activity of levofloxacin and ciprofloxacin on biofilms and planktonic cells of Stenotrophomonas maltophilia isolates from patients with device-associated infections.
    Passerini de Rossi B; García C; Calenda M; Vay C; Franco M
    Int J Antimicrob Agents; 2009 Sep; 34(3):260-4. PubMed ID: 19362452
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A meningitis case due to Stenotrophomonas maltophilia and review of the literature.
    Yemisen M; Mete B; Tunali Y; Yentur E; Ozturk R
    Int J Infect Dis; 2008 Nov; 12(6):e125-7. PubMed ID: 18579427
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An evaluation of different steam disinfection protocols for cystic fibrosis nebulizers.
    Hohenwarter K; Prammer W; Aichinger W; Reychler G
    J Cyst Fibros; 2016 Jan; 15(1):78-84. PubMed ID: 26233897
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nebulizers in cystic fibrosis: a source of bacterial contamination in cystic fibrosis patients?
    Brzezinski LX; Riedi CA; Kussek P; Souza HH; Rosário N
    J Bras Pneumol; 2011; 37(3):341-7. PubMed ID: 21755189
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Melanonychia caused by Stenotrophomonas maltophilia.
    Hamasaka E; Akiyama M; Hata H; Aoyagi S; Shimizu H
    Clin Exp Dermatol; 2009 Mar; 34(2):242-3. PubMed ID: 19120402
    [No Abstract]   [Full Text] [Related]  

  • 53. Identification and management of unusual pathogens in cystic fibrosis.
    Elborn JS
    J R Soc Med; 2008 Jul; 101 Suppl 1(Suppl 1):S2-5. PubMed ID: 18607011
    [No Abstract]   [Full Text] [Related]  

  • 54. Longitudinal study of Stenotrophomonas maltophilia antibody levels and outcomes in cystic fibrosis patients.
    Wettlaufer J; Klingel M; Yau Y; Stanojevic S; Tullis E; Ratjen F; Waters V
    J Cyst Fibros; 2017 Jan; 16(1):58-63. PubMed ID: 27346471
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Air contamination with bacteria in cystic fibrosis clinics: implications for prevention strategies.
    Zuckerman JB; Clock SA; Prato BS; McDevitt JJ; Zhou JJ; Leclair LW; Lucas FL; Saiman L
    Am J Respir Crit Care Med; 2015 Mar; 191(5):598-601. PubMed ID: 25723827
    [No Abstract]   [Full Text] [Related]  

  • 56. Infection control recommendations for patients with cystic fibrosis: Microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission.
    Saiman L; Siegel J;
    Am J Infect Control; 2003 May; 31(3 Suppl):S1-62. PubMed ID: 12762292
    [No Abstract]   [Full Text] [Related]  

  • 57. Repeated hot water and steam disinfection of Pari LC Plus® nebulizers alter nebulizer output.
    Collins MS; O'Brien M; Schramm CM; Murray TS
    J Cyst Fibros; 2019 Mar; 18(2):233-235. PubMed ID: 30224332
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bacterial contamination of cystic fibrosis clinics.
    Zuckerman JB; Zuaro DE; Prato BS; Ruoff KL; Sawicki RW; Quinton HB; Saiman L;
    J Cyst Fibros; 2009 May; 8(3):186-92. PubMed ID: 19250885
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bacterial contamination in the environment of hospitalised children with cystic fibrosis.
    Ferroni A; Werkhauser-Bertrand A; Le Bourgeois M; Beauvais R; Vrielynck S; Durand C; Lenoir G; Berche P; Sermet-Gaudelus I
    J Cyst Fibros; 2008 Nov; 7(6):477-82. PubMed ID: 18550452
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Identification of Stenotrophomonas maltophilia Contamination in Ultrasound Endoscopes and Reproduction of Decontamination Failure by Deliberate Soiling Tests.
    Stigt JA; Wolfhagen MJ; Smulders P; Lammers V
    Respiration; 2015; 89(6):565-71. PubMed ID: 25925975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.